In this section

Clinical trials

Active clinical trials

Cancer Clinical Trials - IIT-BURKE-VENETOCLAX-EPIGENETI


Protocol Summary

    Protocol No
    IIT-BURKE-VENETOCLAX-EPIGENETI
    Principal Investigator
    Zach Graff
    Phase
    I
    Title
    A Phase I Study of Venetoclax to Augment Epigenetic Modification and Chemotherapy in Pediatric and Young Adult Patients with Relapsed and Refractory Acute Myeloid Leukemia
    Associated Disease(s)
    Acute Myelogenous Leukemia (AML)
    Description (Summary)
    In this study, we want to find out if the combination of venetoclax, 5-azacitidine and vorinostat followed by standard chemotherapy will improve survival rates in children and young adults with relapsed AML. Everyone in this study will receive the investigational combination of venetoclax, 5-azacitidine and vorinostat followed by standard chemotherapy. We believe the addition of venetoclax in combination with epigenetic therapy will provide greater treatment response rates than without these drugs, but the effectiveness and safety of this approach is not known. We do not know all the ways that this drug may affect people. This study may not help you, but we hope the information from this study will help us develop a better treatment for relapsed/refractory AML in the future.
    Participating Institutions
    Childrens Hospital of Wisconsin
    ClinicalTrials.gov
Contact us

For more information about cancer and blood disorders clinical trials, email us or call

(414) 955-4727

Get a second opinion

It's important to know what your options are. We can provide expert opinions to verify or give more information about an initial diagnosis. Contact us today.

Why participate in clinical trials?

Michael Burke, MD

"The steady improvement in survival for children with cancer is a direct result of their enrollment onto clinical trials; without which we would remain decades behind in terms of scientific advances in pediatric cancer." ~Michael J. Burke, MD